Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guidant (GDT) -- Ignore unavailable to you. Want to Upgrade?

To: JMS who wrote (57)	12/1/1997 9:31:00 PM
From: B4TheBell	Read Replies (1) \| Respond to of 235

How 'bout that GDT today... I saw the WSJ article. Mentioned defibrillation devices have much better results than drug therapy, naming GDT, MDT and St. Jude (sym?) as players in defib. market. What I think really drove it today was BSX Q4 and FY98 downward earnings revisions by UBS Securities. Analyst took every opportunity to mention GDT... Monday December 1, 10:40 am Eastern Time RESEARCH ALERT-Boston Scientific Q4 EPS view cut NEW YORK, Dec 1 (Reuters) - UBS Securities Inc analyst Emil Westergaard cut his fourth quarter profit forecast for Boston Scientific Inc (NYSE:BSX - news) on Monday to $0.37 a share from $0.44 a share, due to near-term uncertainty. -- He said the cut was based on a previously-announced $15 million inventory write-down, or $0.03 a share, for a recall and some European over-stocking as well as an ''explosive'' launch of a rival product by Guidant Corp (NYSE:GDT - news) on Boston Scientific's over-the-wire balloon angioplasty sales. -- Westergaard also cut 1998 estimates to $2.05 from $2.20 based on the strength of Guidant's multi-link launch, which could cut into Boston Scientific's market share until it launches its own NIR stent, planned for mid-1998. -- Boston Scientific shares were up 10/16 to 45-13/16 while Guidant shares rose 1 to 65-1/4, a new year high. -- In a report, UBS said Guidant is indicating sales of its Multi-Link stent could exceed $90 million, or a 50 percent market share, in the fourth quarter. That news is tempered by the fact that some Guidant stents are being implanted into patients with a longer guidewire that allows physicians to continue to use Boston Scientific's angioplasty balloons, instead of moving to the Guidant products. -- UBS said for its models, it is making conservative assumptions and assuming Boston Scientific loses all balloon catheter sales after a procedure is done with a Guidant product. Says each 20 percent increment of domestic stent market share taken by Guidant shaves $0.01 a share from Boston Scientific's EPS per quarter. -- Boston Scientific meets with the FDA this week concerning its NIR stent filing, UBS said, with PMA (pre-market approval) filing likely in mid-December. B4